European Commission approves triplet therapy formultiple myeloma
Celgene Corporation announced that the European Commission (EC) has approved two new triplet regimens based on Celgene’s proprietary IMiD treatments, Revlimid (lenalidomide) and Imnovid (pomalidomide) for patients with Multiple Myeloma
The approval of the Imnovid triplet (PVd) ( pomalidomide + bortezomib + dexamethasone) was supported by data from OPTIMISMM, the first prospective phase III trial to evaluate an Imnovid-based triplet regimen in patients who were all previously treated with Revlimid, and the majority (70%) of patients were Revlimid refractory. Results from OPTIMISMM were recently published in The Lancet Oncology.
See- Richardson P et al. "OPTIMISMM: Phase III trial of pomalidomide, bortezomib, and low?dose dexamethasone vs bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed or refractory multiple myeloma" (Abstract).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.